Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Amgen's research and development efforts are centered on several key products that could significantly impact its future performance: MariTide, Amgen's candidate for obesity treatment, has emerged ...

MariTide, Amgen's candidate for obesity treatment, has emerged as a focal point for investors. Phase II topline results are expected in late 2024, with analysts anticipating data that could position ...

next MariTide studies start by mid-year 9:06 PM UTC · Updated ago ANALYSISTrade war with China casts dark cloud over new US LNG projects 9:03 PM UTC · Updated ago Reuters, the news and media ...

Helicore’s lead drug, dubbed HCR-188, blocks GIP ligands in digestive cells, setting it apart from drugs like Eli Lilly’s Zepbound and Amgen’s MariTide, which take aim at GIP receptors found ...